Ocular Delivery of Proteins and Peptides

  • Lunawati BennettEmail author


Biotechnology is steadily becoming an important component of the pharmaceutical industry. The numbers of protein and peptide ocular based drugs being developed have increased. The technique to formulate peptide or protein ocular drugs is very different from formulating conventional small molecule drugs. Additionally, the delivery of a peptide or protein-based drugs is particularly challenging due to the issues of protein instability. This chapter discusses the development of proteins and peptides for ocular delivery with an emphasis on their specific considerations and challenges, and a role of specific proteins such as alpha crystallins and thymosin β4 in ocular drug delivery. Possible routes of protein ocular drug delivery are also discussed.


Ocular peptides delivery Proteins delivery Peptides delivery Route of delivery 


  1. Aksungur P, Demirbilek M, Denkbas EB et al (2011) Development and characterization of cyclosporine a loaded nanoparticles for ocular drug delivery: cellular toxicity, uptake, and kinetic studies. J Control Rel. 151(3):286–294CrossRefGoogle Scholar
  2. Amaral J, Fariss RN, Campos MM et al (2005) Transscleral-RPE permeability of PEDf and ovalbumin proteins: implications for subconjunctival protein delivery. Invest Opthalmol Vis Sci. 46(12):4383–4392CrossRefGoogle Scholar
  3. Ambati J, Gragoudas ES, Miller JW et al (2000) Transcleral delivery of bioactive protein to the choroid and retina. Invest Opthamol Vis Sci. 41(5):1186–1191Google Scholar
  4. Bloemendal H, deJong WW (1991) Lens proteins and their genes. Prog Nucleic Acid Res Mol Biol 41:259–281CrossRefGoogle Scholar
  5. Do DV, Nguyen QD, Shah SM et al (2009) An exploratory study of the safety, tolerability, and bioactivity of a single intravitreal injection of vascular endothelial growth factor trap-eye in patients with diabetic macular edema. Br J Opthamol. 93(2):144–149CrossRefGoogle Scholar
  6. Fort PE, Freeman WM (2009) The retinal proteome in experimental diabetic retinopathy: up-regulation of crystallins and reversal by systemic and periocular insulin. Mol Cell Proteomics 8(4):767–779CrossRefGoogle Scholar
  7. Fort PE, Lampi KJ (2011) New focus on alpha-crystallins in retinal neurodegenerative diseases. Exp Eye Res 92:98–103CrossRefGoogle Scholar
  8. Gaudana R, Jwala J, Boddu SHS, Mitra AK (2009) Recent perspective in ocular drug delivery. Pharm Res 26(5):1197–1216CrossRefGoogle Scholar
  9. Goldstein AL, Hannappel E, Sosne G et al (2012) Thymosin beta 4: a multi-functional regenerative peptide. Expert Opin Biol. 12:37–51CrossRefGoogle Scholar
  10. Ibraheem D, Elaissari A, Fessi H (2014) Administration strategies for proteins and peptides. Int J Pharm 477:578–589CrossRefGoogle Scholar
  11. Kompella UB, Amrite AC, Ravi RP, Durazo SA (2013) Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res. 36:172–198CrossRefGoogle Scholar
  12. Mitragotri S, Burke P, Langer R (2014) Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 13:655–672CrossRefGoogle Scholar
  13. Mprishita M, Peppas NA (2006) Is the oral route possible for peptide and protein drug delivery? Drug Discov Today 11:905–910CrossRefGoogle Scholar
  14. Nguyen QD, Shah SM, Browning DJ et al (2009) A phase 1 study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Opthamol. 116(11):2141–2148CrossRefGoogle Scholar
  15. Santhoshkumar P, Murugesan R (2009) Deletion of (54) FRAPSWF (61) residues decreases the oligomeric size and enhances the chaperone function of alphaB-crystallin. Biochemistry 48(23):5066–5073CrossRefGoogle Scholar
  16. Sanharawi ME, Kowalczuk L, Touchard E et al (2010) Protein delivery for retinal diseases: from basic considerations to clinical applications. Progr Retin Eye Res 229:443–465CrossRefGoogle Scholar
  17. Sinha VR, Trehan A (2003) Biodegradable microspheres for protein delivery. J Control Rel 90:261–280CrossRefGoogle Scholar
  18. Sosne G, Albeiruti A, Hollis B et al (2006) Thymosin beta 4 inhibits benzalkonium chloride-mediated apoptosis in corneal and conjunctival epithelial cells in vitro. Exp Eye Res 83:502–507CrossRefGoogle Scholar
  19. Sosne G, Kleinman HK (2015) Primary mechanisms of thymosin β4 repair activity in dry eye disorders and other tissue injuries. Invest Opthalmol Vis Sci 56:5110–5117CrossRefGoogle Scholar
  20. Sosne G, Kim C, Dunn SP (2015) Thymosin beta 4 significantly improves signs and symptoms of severe dry eye in phase 2 clinical trial. Cornea 34:491–496CrossRefGoogle Scholar
  21. Torchilin VP, Lukyanov AN (2003) Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today 8:259–266CrossRefGoogle Scholar
  22. Vadlapudi AD, Patel A, Cholkar K (2012) Mitra AK. Recent patents on emerging therapeutics for the treatment of glaucoma, age-related macular degeneration, and uveitis. Recent Pat Biomed Eng 5(1):83–101CrossRefGoogle Scholar
  23. Witting M, Obst K, Friess W, Hedtrich S (2015) Recent advances in topical delivery of proteins and peptides mediated by soft matter nanocarriers. J Biotech Adv. 33:1355–1369CrossRefGoogle Scholar
  24. Yang SC, Lu LF, Cai Y et al (1999) Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Rel 59:299–307CrossRefGoogle Scholar
  25. Zhou XH, Po LW (1991) Peptide and protein drugs: therapeutic applications, absorption, and parenteral administration. Int J Pharm 75:97–115Google Scholar

Copyright information

© Springer International Publishing AG 2016

Authors and Affiliations

  1. 1.School of PharmacyUnion UniversityJacksonUSA

Personalised recommendations